Shots: The US FDA has accepted the sBLA and EMA has validated the type-II variation application for Beovu (brolucizumab, 6mg) for the treatment of DME. Additionally, the PMDA has accepted […]readmore
Tags : Beovu
Shots: The company reported 2yrs. & 1 yrs. results from P-III KITE & KINGFISHER studies evaluating Beovu (6mg, q4w) vs aflibercept (2mg) in 926 patients with DME across 36 countries […]readmore
Shots: The P- III MERLIN study involves assessing the efficacy & safety of Beovu (6 mg, q4w) vs aflibercept (2 mg, q4w) following the loading phase in patients with wet […]readmore
Shots: The company reported the 1yrs. results from the P-III KESTREL & KITE studies assessing Beovu (6mg) vs aflibercept (2mg) in 926 patients with DME across 36 countries Results: met […]readmore
Shots: The P-III HAWK (6/3mg) & HARRIER (6mg) study assessing Beovu [q12w/q8w with the majority on q12w following the loading phase) vs aflibercept (2mg) in 1,800 patients with wet AMD […]readmore
Shots: The EU label update includes additional categorization of retinal vasculitis and/or retinal vascular occlusion, usually in the intraocular inflammation. The approval follows Novartis completion of safety review and initiation […]readmore
Shots: The P-III KITE involves assessing of Beovu (brolucizumab, 6mg) vs aflibercept (2mg) in 360 patients with DME across 80 centers in 23 countries. In 2EPs, more than half of […]readmore
Shots: The EC’s approval is based on P-III HAWK (6/3mg) & HARRIER (6mg) study assessing Beovu [q12w/q8w with the majority on q12w following the loading phase) vs aflibercept 2 mg […]readmore
Shots: The approval is based on P-III HAWK (NCT02307682) & HARRIER (NCT02434328) studies involves assessing of Beovu (intravitreal injection), 6mg (HAWK and HARRIER) & 3mg (HAWK) vs Aflibercept (2mg) in […]readmore